This company listing is no longer active
Resumen de acción 0RAQ
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Competidores de Karo Pharma AB (publ)
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | kr60.53 |
| 52 Week High | kr62.00 |
| 52 Week Low | kr49.25 |
| Beta | 0.10 |
| 1 Month Change | 0.21% |
| 3 Month Change | 0.88% |
| 1 Year Change | 4.54% |
| 3 Year Change | 57.63% |
| 5 Year Change | 55.16% |
| Change since IPO | -49.56% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 0RAQ | GB Pharmaceuticals | Mercado GB | |
|---|---|---|---|
| 7D | 0.2% | 1.7% | 1.0% |
| 1Y | 4.5% | 5.2% | 3.0% |
Rentabilidad vs. Industria: 0RAQ exceeded the UK Pharmaceuticals industry which returned 3.4% over the past year.
Rentabilidad vs. Mercado: 0RAQ exceeded the UK Market which returned -9% over the past year.
Volatilidad de los precios
| 0RAQ volatility | |
|---|---|
| 0RAQ Average Weekly Movement | 0.3% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Precio estable de las acciones: 0RAQ has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: 0RAQ's weekly volatility (0%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 225 | Christoffer Lorenzen | www.karopharma.com |
Resumen de fundamentos de Karo Pharma AB (publ)
| Estadísticas fundamentales de 0RAQ | |
|---|---|
| Capitalización bursátil | kr16.59b |
| Beneficios(TTM) | -kr189.85m |
| Ingresos (TTM) | kr3.47b |
4.8x
Ratio precio-ventas (PS)-87.4x
Ratio precio-beneficio (PE)¿Está 0RAQ sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 0RAQ | |
|---|---|
| Ingresos | kr3.47b |
| Coste de los ingresos | kr1.50b |
| Beneficio bruto | kr1.96b |
| Otros gastos | kr2.15b |
| Beneficios | -kr189.85m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.69 |
| Margen bruto | 56.67% |
| Margen de beneficio neto | -5.48% |
| Ratio deuda/patrimonio | 104.8% |
¿Cómo se ha desempeñado 0RAQ a largo plazo?
Ver rendimiento histórico y comparativa